Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2020 14:35 ET | Source: Revive Therapeutics Ltd.

Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.

TORONTO, March 05, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel psychedelic and...
February 18, 2020 08:41 ET | Source: Revive Therapeutics Ltd.

Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis

TORONTO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based and...
February 12, 2020 09:00 ET | Source: Revive Therapeutics Ltd.

Revive Enters into Psychedelics Market with Letter of Intent to Acquire Psilocin Pharma Corp.

TORONTO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) is pleased to announce that it has entered into a letter of intent, dated February 11, 2020 (the...
February 11, 2020 17:00 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces Brokered Private Placement of up to $2 million

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 11, 2020 (GLOBE NEWSWIRE)...
February 10, 2020 07:00 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics to Pursue the Psychedelic Market With Agreement and Investment in Red Light Holland Financing

TORONTO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is...
February 05, 2020 08:08 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces Offering of $210,000 of Convertible Debenture Units

TORONTO, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is...
January 20, 2020 09:00 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation

TORONTO, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare...
January 06, 2020 09:22 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Provides Update on its Clinical Development Plan For Rare Liver Diseases

TORONTO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare...
December 27, 2019 17:22 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Announces Grant of Stock Options

TORONTO, Dec. 27, 2019 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on the research, development, and...
December 19, 2019 07:00 ET | Source: Revive Therapeutics Ltd.

Revive Therapeutics Provides Update on its Cannabis-based Pharmaceutical Initiatives

TORONTO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on the research, development, and...